

Giovanni Rossi

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1644674/publications.pdf>

Version: 2024-02-01

26
papers

760
citations

567144

15
h-index

580701

25
g-index

26
all docs

26
docs citations

26
times ranked

1279
citing authors

#	ARTICLE	IF	CITATIONS
1	Serum levels of VCAM α 1 are associated with survival in patients treated with nivolumab for NSCLC. European Journal of Clinical Investigation, 2022, 52, e13668.	1.7	5
2	Exploring Response to Immunotherapy in Non-Small Cell Lung Cancer Using Delta-Radiomics. Cancers, 2022, 14, 350.	1.7	22
3	Prognostic value of immunotherapy-induced organ inflammation assessed on 18FDG PET in patients with metastatic non-small cell lung cancer. European Journal of Nuclear Medicine and Molecular Imaging, 2022, 49, 3878-3891.	3.3	3
4	A Circulating Risk Score, Based on Combined Expression of Exo-miR-130a-3p and Fibrinopeptide A, as Predictive Biomarker of Relapse in Resectable Non-Small Cell Lung Cancer Patients. Cancers, 2022, 14, 3412.	1.7	4
5	Radiomic Detection of EGFR Mutations in NSCLC. Cancer Research, 2021, 81, 724-731.	0.4	57
6	Metabolic Parameters as Biomarkers of Response to Immunotherapy and Prognosis in Non-Small Cell Lung Cancer (NSCLC): A Real World Experience. Cancers, 2021, 13, 1634.	1.7	23
7	Safety and efficacy of immune checkpoint inhibitors in non-small-cell lung cancer: focus on challenging populations. Immunotherapy, 2021, 13, 509-525.	1.0	3
8	Cancer pathways analysis and correlation with survival in patients with advanced stage non-small cell lung cancer treated with PD-1 inhibitor.. Journal of Clinical Oncology, 2021, 39, e21007-e21007.	0.8	0
9	The Role of the Immune Metabolic Prognostic Index in Patients with Non-Small Cell Lung Cancer (NSCLC) in Radiological Progression during Treatment with Nivolumab. Cancers, 2021, 13, 3117.	1.7	17
10	Current state of the art and future perspectives with immunotherapy in the management of small cell lung cancer. Expert Review of Respiratory Medicine, 2021, 15, 1427-1435.	1.0	13
11	Comparison Between ¹⁸ F-FDG PET-Based and CT-Based Criteria in Non-Small Cell Lung Cancer Patients Treated with Nivolumab. Journal of Nuclear Medicine, 2020, 61, 990-998.	2.8	44
12	Liquid Biopsy in Non-Small Cell Lung Cancer: Highlights and Challenges. Cancers, 2020, 12, 17.	1.7	82
13	Precision Medicine for NSCLC in the Era of Immunotherapy: New Biomarkers to Select the Most Suitable Treatment or the Most Suitable Patient. Cancers, 2020, 12, 1125.	1.7	43
14	Association Between Response to Nivolumab Treatment and Peripheral Blood Lymphocyte Subsets in Patients With Non-small Cell Lung Cancer. Frontiers in Immunology, 2020, 11, 125.	2.2	53
15	Resistin is associated with overall survival in non-small cell lung cancer patients during nivolumab treatment. Clinical and Translational Oncology, 2020, 22, 1603-1610.	1.2	3
16	Nivolumab treatment in advanced lung cancer patient with chronic active hepatitis C and systemic lupus erythematosus. Immunotherapy, 2019, 11, 873-879.	1.0	12
17	Baseline serum levels of osteopontin predict clinical response to treatment with nivolumab in patients with non-small cell lung cancer. Clinical and Experimental Metastasis, 2019, 36, 449-456.	1.7	15
18	Serum PCSK9 levels at the second nivolumab cycle predict overall survival in elderly patients with NSCLC: a pilot study. Cancer Immunology, Immunotherapy, 2019, 68, 1351-1358.	2.0	24

#	ARTICLE	IF	CITATIONS
19	Prognostic Relevance of Circulating Tumor Cells and Circulating Cell-Free DNA Association in Metastatic Non-Small Cell Lung Cancer Treated with Nivolumab. <i>Journal of Clinical Medicine</i> , 2019, 8, 1011.	1.0	45
20	Concomitant medications during immune checkpoint blockage in cancer patients: Novel insights in this emerging clinical scenario. <i>Critical Reviews in Oncology/Hematology</i> , 2019, 142, 26-34.	2.0	49
21	Correlation between B7-H4 and Survival of Non-Small-Cell Lung Cancer Patients Treated with Nivolumab. <i>Journal of Clinical Medicine</i> , 2019, 8, 1566.	1.0	26
22	The role of CEA, CYFRA21-1 and NSE in monitoring tumor response to Nivolumab in advanced non-small cell lung cancer (NSCLC) patients. <i>Journal of Translational Medicine</i> , 2019, 17, 74.	1.8	103
23	Serial Troponin for Early Detection of Nivolumab Cardiotoxicity in Advanced Non-Small Cell Lung Cancer Patients. <i>Oncologist</i> , 2018, 23, 936-942.	1.9	69
24	Acquired resistance in oncogene-addicted non-small-cell lung cancer. <i>Future Oncology</i> , 2018, 14, 29-40.	1.1	18
25	Releasing the brake: safety profile of immune check-point inhibitors in non-small cell lung cancer. <i>Expert Opinion on Drug Safety</i> , 2017, 16, 573-585.	1.0	21
26	New systemic strategies for overcoming resistance to targeted therapies in non-small cell lung cancer. <i>Expert Opinion on Pharmacotherapy</i> , 2017, 18, 19-33.	0.9	6